| Through the looking glass: understanding non-inferiority J Schumi, JT Wittes Trials 12, 1-12, 2011 | 428 | 2011 |
| Prediction intervals for neural networks via nonlinear regression RD De VlEAUX, J Schumi, J Schweinsberg, LH Ungar Technometrics 40 (4), 273-282, 1998 | 238 | 1998 |
| Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial JC Tardif, JJV McMurray, E Klug, R Small, J Schumi, J Choi, J Cooper, ... The Lancet 371 (9626), 1761-1768, 2008 | 231 | 2008 |
| Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials AM Wessels, PN Tariot, JA Zimmer, KJ Selzler, SM Bragg, SW Andersen, ... JAMA Neurology 77 (2), 199-209, 2020 | 169 | 2020 |
| Changes In Physician Supply And Scope Of Practice During A Malpractice Crisis: Evidence From Pennsylvania: Physicians left medical practice during this time period, but not … MM Mello, DM Studdert, J Schumi, TA Brennan, WM Sage Health Affairs 26 (Suppl2), w425-w435, 2007 | 38 | 2007 |
| Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814). JR Sims, KJ Selzler, AM Downing, BA Willis, CD Aluise, J Zimmer, ... The journal of prevention of Alzheimer's disease 4 (4), 247-254, 2017 | 27 | 2017 |
| Disease modification in Alzheimer’s disease: current thinking H Liu-Seifert, J Schumi, X Miao, Y Tian, M Rabbia, SW Andersen, ... Therapeutic Innovation & Regulatory Science 54, 396-403, 2020 | 19 | 2020 |
| Aggressive reduction of inflammation stops events trial, i., effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled … JC Tardif, JJ McMurray, E Klug, R Small, J Schumi, J Choi, J Cooper, ... Lancet 371, 1761-1768, 2008 | 13 | 2008 |
| Etesian: a phase 2b study of the efficacy, safety and tolerability of azd8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia MJ Koren, A Hofherr, J Schumi, D Rekic, J Knochel, CAM Nilsson, ... Journal of the American College of Cardiology 79 (9_Supplement), 1475-1475, 2022 | 10 | 2022 |
| Resampling‐based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility J Schumi, V DeGruttola Statistics in medicine 27 (23), 4740-4757, 2008 | 9 | 2008 |
| PROXYMO DEMONSTRATES SAFETY AND EFFICACY OF COTADUTIDE, A NOVEL INCRETIN CO-AGONIST IN BIOPSY-PROVEN NON-CIRRHOTIC NASH WITH FIBROSIS D Robertson, B Challis, SJ Daniels, J Sarv, J Sanchez, J Schumi, ... HEPATOLOGY 74 (6), 1386A-1386A, 2021 | 6 | 2021 |
| Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans E Ericson, L Bergenholm, AC Andréasson, CI Dix, J Knöchel, SF Hansson, ... Hepatology Communications 6 (10), 2689-2701, 2022 | 3 | 2022 |
| Assessment of the cardiovascular risk of olmesartan medoxomil-based treatment: meta-analysis of individual patient data AC Wang, U Stellmacher, J Schumi, N Tu, PE Reimitz American Journal of Cardiovascular Drugs 16, 427-437, 2016 | 3 | 2016 |
| The PCSK9-Targeted Antisense Oligonucleotide AZD8233 Reduces LDL-C, ApoB, and Lp (a) in Patients With Dyslipidemia on Statin Treatment-Data From the Phase 2b ETESIAN Study A Hofherr, J Schumi, A Rudvik, R Vega, T Ryden-Bergsten, ... Circulation 146 (Suppl_1), A11482-A11482, 2022 | 2 | 2022 |
| Testing for associations with missing high-dimensional categorical covariates J Schumi, AG DiRienzo, V DeGruttola The international journal of biostatistics 4 (1), 2008 | 2 | 2008 |
| DT‐01‐04: LANABECESTAT: BASELINE CHARACTERISTICS OF PARTICIPANTS RANDOMIZED IN THE PHASE 2/3 AMARANTH STUDY JR Sims, ACM Downing, SW Andersen, AM Wessels, JA Zimmer, J Mullen, ... Alzheimer's & Dementia 14 (7S_Part_31), P1666-P1666, 2018 | 1 | 2018 |
| Resampling-based methods for multiple hypothesis testing JA Schumi Harvard University, 2006 | 1 | 2006 |
| ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia A Hofherr, J Schumi, D Rekić, J Knöchel, CAM Nilsson, A Rudvik, ... Atherosclerosis 355, 28, 2022 | | 2022 |
| Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Commentary SJ DUFFY, AM DART, JC TARDIF, JJV MCMURRAY, E KLUG, R SMALL, ... Lancet 371 (9626), 2008 | | 2008 |
| DO BULLETS HAVE FINGERPRINTS? Preliminary Graphical Partitioning by Trace Element Concentration for Bullet Fragment Data J Schumi, S Collaborative Proceedings of the Section on Statistical Graphics, 11, 1999 | | 1999 |
